Submit Manuscript  

Article Details


Evaluation of antibodies directed against two GPCRs, anti-AT1R and anti-ETAR, on kidney transplant outcome: Own experience and review of the topic

Author(s):

El Kaaoui El Band J, S. Llorente, Martinez-Garcia P, Alfaro R, Jimenez-Coll V, Boix F, Galian JA, Martinez-Banaclocha H, Botella C, Moya-Quiles MR, Minguela A, Legaz I and Muro M*  

Abstract:


Background: The role of an alloimmune response against non-self-antigens is established in organ transplantation. The main actors of this recognition are the HLA incompatibilities between donor and recipient, but may also involve reactivity against other alloantigens expressed on the allograft and result from an autoimmune response developed against self-antigens.

Objective: Our study aimed to determine the presence of non-anti-HLA antibodies (anti-AT1R and anti-ETAR) in sera from patients with end-stage renal disease who underwent kidney transplantation in pre-and post-transplantation samples and study their influence on the development and evolution of acute humoral rejections and DSAs.

Method: In this sense, antibodies (Abs) against two G protein-coupled receptors (GPCRs), angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR), have been detected in the sera of transplant recipients who experience allograft dysfunction, patients with coronary heart disease, marginal hypertension and refractory, vascular lesions, myocardial hypertrophy and chronic inflammatory diseases such as atherosclerosis or sclerosis.

Results: In our own experience, kidney graft recipients were monitored for anti-ETAR, -AT1R, and -HLA Abs in pre-and post-transplant evolution, and anti-AT1R and/or -ETAR Abs were detected in 24% of recipients (22.4% with anti-AT1R Abs and 9.8% with anti-ETAR Abs). Due to acute humoral rejection, Graft loss was detected in 6.4% of patients with anti-GPCRs non-HLA Abs, and 3.2% had DSA anti-HLA Abs. In this research and review paper, we bring together our own experience, also how to function the anti-GPCRs autoAbs and how these Abs that activate GPCRs could influence graft outcome. Conclusion. Therefore, in conclusion, there is a high association of non-HLA anti-GPCRs Abs levels with reduced kidney function after transplantation, especially in the presence of DSA anti-HLA Abs. Although more studies are needed, anti-AT1R and anti-ETAR antibodies may be helpful biomarkers that allow the risk of graft loss to be assessed.

Keywords:

Non-HLA antibodies, Ac AT1R, Ac ETAR, DSAs, humoral rejection, kidney transplant, antibody-mediated rejection, medical death certificates

Affiliation:

Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Department of Legal and Forensic Medicine, Biomedical Research Institute (IMIB), Regional Campus of International Excellence “Campus Mare Nostrum”, Faculty of Medicine, University of Murcia, 30100 Murcia, Immunology and Nephrology Services, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia



Full Text Inquiry